Physician

Christopher A. D'Arcy, M.D.

According to 2025 Medicare claims, Christopher D'Arcy, M.D. (NPI: 1073560330) practices rheumatology in the Providence-Warwick, RI-MA market, with the plurality of this provider's patient population coming from Washington, RI. This provider's primary affiliated billing organization is COASTAL RHEUMATOLOGY PC INC (NPI: 1851310890; TIN: 050518460) and primary practice location at 02891-2927.

D'Arcy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 667 traditional Medicare patients, billed 157,452 HCPCS/CPT codes, and received $1,023,754 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 8,192 prescription claims across 999 beneficiaries totaling $4,668,725 in drug costs, led by Enbrel Sureclick (Etanercept). 2023 DME data shows 22 claims. Open Payments data shows 100 records totaling $1,624. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,575,565 to $4,668,725. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	854	73,930	$728,949
2016	855	72,414	$842,610
2017	860	85,847	$972,940
2018	902	82,483	$920,508
2019	879	106,018	$1,101,871
2020	812	93,628	$968,371
2021	762	107,479	$939,306
2022	697	90,758	$735,305
2023	694	128,941	$927,851
2024	667	157,452	$1,023,754

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	807	7,409	$1,575,565
2016	823	7,816	$1,785,612
2017	841	7,589	$2,035,145
2018	870	7,853	$2,354,101
2019	910	7,368	$2,660,069
2020	896	7,537	$2,854,507
2021	900	7,596	$3,230,444
2022	913	7,610	$3,281,554
2023	972	7,964	$3,552,740
2024	999	8,192	$4,668,725

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	12	$424
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	22	$2,061
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	200	339	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	465	1,075	$64
99442	Telephone medical discussion with physician, 11-20 minutes	196	314	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	352	615	$12
96372	Injection of drug or substance under skin or into muscle	87	157	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	111	3,388	$938,555
Humira(Cf) Pen	Adalimumab	106	3,528	$936,326
Enbrel	Etanercept	29	1,204	$337,525
Humira(Cf)	Adalimumab	37	1,092	$274,063
Rinvoq	Upadacitinib	32	960	$235,879

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	100	$1,624	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher A. D'Arcy, M.D.?

Tedicare shows public-source Medicare data for Christopher A. D'Arcy, M.D. (NPI 1073560330), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher A. D'Arcy, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher A. D'Arcy, M.D.?

Christopher A. D'Arcy, M.D. is linked to COASTAL RHEUMATOLOGY PC INC (billing NPI 1851310890) in the available physician profile data.

Does Christopher A. D'Arcy, M.D. have Open Payments data?

Christopher A. D'Arcy, M.D. has 100 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.